From: Verifying the fully “Laplacianised” posterior Naïve Bayesian approach and more
Activity class | Target ID | No. of active compounds |
---|---|---|
Adenosine A2a receptor | 252 | 424 |
Adenosine A3 receptor | 280 | 356 |
Adenosine A1 receptor | 114 | 322 |
Cannabinoid CB2 receptor | 259 | 319 |
Histamine H3 receptor | 10280 | 314 |
Cannabinoid CB1 receptor | 87 | 304 |
Dopamine D2 receptor | 72 | 281 |
Mu opioid receptor | 129 | 269 |
Kappa opioid receptor | 137 | 244 |
Delta opioid receptor | 136 | 223 |
Melanocortin receptor 4 | 10142 | 220 |
Serotonin 1a (5-HT1a) receptor | 51 | 215 |
Dopamine D3 receptor | 130 | 213 |
Melanin-concentrating hormone receptor 1 | 19905 | 206 |
Serotonin 6 (5-HT6) receptor | 10627 | 173 |
Serotonin 2a (5-HT2a) receptor | 107 | 155 |
C-C chemokine receptor type 2 | 11575 | 150 |
Adenosine A2b receptor | 278 | 136 |
G protein-coupled receptor 44 | 20174 | 117 |
Serotonin 2c (5-HT2c) receptor | 108 | 114 |
Histamine H4 receptor | 11290 | 96 |
C-C chemokine receptor type 5 | 10580 | 91 |
Nociceptin receptor | 138 | 89 |